These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 13696225)

  • 1. Unpredictability of antibody response of infants to injections of Salk poliomyelitis vaccine.
    CRAMBLETT HG; FOMON SJ
    J Pediatr; 1961 Jun; 58():779-84. PubMed ID: 13696225
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody response to Salk vaccine in Norwegian school children.
    ULSTRUP JC; MEMMER R
    Arch Gesamte Virusforsch; 1959; 9():343-7. PubMed ID: 13840329
    [No Abstract]   [Full Text] [Related]  

  • 3. Complement-fixing antibody response to inactivated poliovirus vaccine.
    LENNETTE EH; SCHMIDT NJ; MAGOFFINRL
    J Immunol; 1961 Dec; 87():696-706. PubMed ID: 14464005
    [No Abstract]   [Full Text] [Related]  

  • 4. [Formation and persistence of antibodies against poliomyelitis after vaccinations with Salk vaccine. A contribution to the value and limitations of Salk vaccinations].
    BUERGIN-WOLFF A; BERGER E
    Schweiz Med Wochenschr; 1960 Jun; 90():633-7. PubMed ID: 13805708
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactions to the salk polio vaccine injections of April 1955.
    DAVIS PL
    Med Times; 1956 Jul; 84(7):707-9. PubMed ID: 13347478
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced "Salk vaccine" of children totally or partially susceptible to poliovirus infection.
    GELFAND HM; LeBLANC DR; FOX JP; POTASH L
    Am J Hyg; 1959 Nov; 70():303-11. PubMed ID: 13827181
    [No Abstract]   [Full Text] [Related]  

  • 7. The antibody response in children vaccinated with a) live attenuated polioviruses (Sabin) and b) the fourth dose of inactivated poliovaccine.
    ZACEK K; VONKA V; ADAM E
    J Hyg Epidemiol Microbiol Immunol; 1961; 5():178-88. PubMed ID: 13787597
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the development of natural immunity to poliomyelitis in Louisiana. VI. The incidence of poliovirus infections during 1958 as an indication of the effect of Salk-type vaccine on virus dissemination.
    POTASH L; GELFAND HM; FOX JP
    Am J Hyg; 1960 May; 71():418-26. PubMed ID: 14434441
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies of Rh sensitivity after repeated injections of Salk vaccine.
    ABELSON NM; MCALLISTER RM; GREENE A; CORIELL LL
    J Am Med Assoc; 1955 Sep; 159(4):238-41. PubMed ID: 13251868
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preparation and control of the Salk vaccine against poliomyelitis].
    DE SOMER P
    Belg Tijdschr Geneesk; 1956 Aug; 12(16):841-52. PubMed ID: 13355838
    [No Abstract]   [Full Text] [Related]  

  • 11. Serologic response of nonimmune subjects to commercial Salk vaccine. Response and antibody persistence with four doses.
    LEPOW ML; CARVER DH; ROBBINS FC
    Am J Dis Child; 1962 Jun; 103():803-11. PubMed ID: 14464186
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical observations on children vaccinated against poliomyelitis (Salk vaccine)].
    FUTER DS; IAMPOL'SKAIA EI
    Sov Med; 1960 Jun; 24():9-16. PubMed ID: 13825787
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal exfoliative dermatitis following injection of triple antigen and Salk vaccine.
    IAMS AM
    Am J Dis Child; 1960 Aug; 100():282-5. PubMed ID: 14405795
    [No Abstract]   [Full Text] [Related]  

  • 14. Some statistical aspects of safety testing the Salk poliomyelitis vaccine.
    CORNFIELD J; HALPERIN M; MOORE F
    Public Health Rep (1896); 1956 Oct; 71(10):1045-56. PubMed ID: 13370807
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of Salk vaccine in reducing nonparalytic poliomyelitis in a large urban epidemic.
    MARINE WM; CHIN TD; GRAVELLE CR; SOERGEL ME
    N Engl J Med; 1961 May; 264():903-7. PubMed ID: 13766783
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis.
    MELNICK JL; BENYESH-MELNICK M; PENA R; YOW M
    JAMA; 1961 Apr; 175():1159-62. PubMed ID: 13769273
    [No Abstract]   [Full Text] [Related]  

  • 17. [On neutralizing antibodies before and after vaccination against poliomyelitis with Salk vaccine].
    GILLERT KE; GRUETZNER L; HARTMANN H
    Zentralbl Bakteriol; 1960 Feb; 177():289-98. PubMed ID: 13850076
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous eruptions after use of Salk poliomyelitis vaccine.
    STROUD GM; BRODELL HL; LASCHEID WP; POTTS LW
    J Am Med Assoc; 1958 Jan; 166(3):251-3. PubMed ID: 13491335
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of roosters in the antigenicity testing of Salk poliomyelitis vaccine.
    FURESZ J; MOREAU P
    J Immunol; 1963 Feb; 90():192-200. PubMed ID: 13945854
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of Salk vaccine use in Delaware.
    HUDSON FI
    Del State Med J; 1956 Sep; 28(9):215-6. PubMed ID: 13365302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.